The projected annual revenue for Glaukos is 386MM, an increase of 7.12%. The projected annual non-GAAP EPS is -1.45. IJR - iShares Core S&P Small-Cap ETF holds 3,492K shares representing 6.34% ...
FDA set an Oct. 20, 2025, review deadline for Glaukos' Epioxa NDA ... Join Nic Chahine live on Wednesday, March 19, at 6 PM ET for a step-by-step breakdown of how to to capitalize on post-Fed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback